Romagnuolo Joseph, Andrews Christopher N, Bain Vincent G, Bonacini Maurizio, Cotler Scott J, Ma Mang, Sherman Morris
Digestive Disease Center, University of South Carolina, 96 Jonathon Lucas Street, PO Box 250 327, Charleston, SC 29425, USA.
Scand J Gastroenterol. 2005 Nov;40(11):1365-71. doi: 10.1080/00365520500287400.
A recent single-center multivariate analysis of hepatitis C (HCV) patients showed that having any two criteria: 1) ferritin > or =200 microg/l and 2) spider nevi and/or albumin < or = 35 g/l predicted grade 2 or greater histological inflammation; the presence of any two of the following criteria: spider nevi, platelets < or =150 x 109/l, palpable splenomegaly and/or albumin < or =35 g/l predicted stage 2 or greater histological fibrosis. Absence of predictors also predicted a lack of inflammation and fibrosis. Our aim was prospectively to validate this clinical prediction model using an independent multicenter sample.
Eighty-one patients with previously untreated active chronic HCV underwent physical examination, laboratory investigation, and liver biopsy. Biopsies were read, in blinded fashion, by a single pathologist, using a modified Hytiroglou (1995) scale. The clinical scoring system was correlated with histology; likelihood ratios (LRs), Fisher's exact p-values, and receiver operating characteristics (ROCs) were calculated.
Data recording was complete in 77 and 38 patients regarding fibrotic stage and inflammatory grade, respectively. For fibrosis, 3/3 patients with any three criteria (LR 17, positive predictive value (PPV) 100%), 4/5 patients with any two criteria (LR 5.1), and 15/47 with no criteria (LR 0.6, negative predictive value (NPV) 68%) had stage 2 or greater fibrosis on biopsy (p=0.01). For inflammation, 5/5 patients with both criteria (LR 15, PPV 100%), and 8/19 patients with no criteria (LR 0.5, NPV 58%) had moderate-severe inflammation on liver biopsy (p=0.036). When missing variables were assumed to be normal, recalculated LRs were almost identical. An alanine aminotransferase (ALAT) level <60 U/l may increase the NPVs.
This independent multicenter data set has validated our published model which uses simple clinical variables accurately and significantly to predict hepatic fibrosis and inflammation in HCV patients.
最近一项针对丙型肝炎(HCV)患者的单中心多变量分析表明,具备以下任意两条标准:1)铁蛋白≥200μg/l以及2)蜘蛛痣和/或白蛋白≤35g/l可预测组织学炎症为2级或更高;具备以下任意两条标准:蜘蛛痣、血小板≤150×10⁹/l、可触及的脾肿大和/或白蛋白≤35g/l可预测组织学纤维化达到2期或更高。不存在预测指标也预示着无炎症和纤维化。我们的目的是使用独立的多中心样本对该临床预测模型进行前瞻性验证。
81例既往未经治疗的活动性慢性HCV患者接受了体格检查、实验室检查及肝活检。活检结果由一名病理学家采用改良的Hytiroglou(1995年)评分系统进行盲法解读。将临床评分系统与组织学结果进行关联分析;计算似然比(LRs)、Fisher精确p值及受试者工作特征曲线(ROCs)。
分别有77例和38例患者的纤维化分期及炎症分级数据记录完整。对于纤维化,活检显示具备任意三条标准的3/3例患者(LR 17,阳性预测值(PPV)100%)、具备任意两条标准的4/5例患者(LR 5.1)以及无标准的15/47例患者(LR 0.6,阴性预测值(NPV)68%)存在2期或更高的纤维化(p = 0.01)。对于炎症,具备两条标准的5/5例患者(LR 15,PPV 100%)以及无标准的8/19例患者(LR 0.5,NPV 58%)肝活检显示有中度至重度炎症(p = 0.036)。当假定缺失变量为正常时,重新计算的LRs几乎相同。丙氨酸转氨酶(ALAT)水平<60 U/l可能会提高NPVs。
这个独立的多中心数据集验证了我们已发表的模型,该模型使用简单的临床变量能够准确且显著地预测HCV患者的肝纤维化和炎症。